Anika Therapeutics Inc
NASDAQ:ANIK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Anika Therapeutics Inc
PP&E Net
Anika Therapeutics Inc
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Anika Therapeutics Inc
NASDAQ:ANIK
|
PP&E Net
$66.3m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
5%
|
|
|
Abbvie Inc
NYSE:ABBV
|
PP&E Net
$5.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
PP&E Net
$5.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
PP&E Net
$7.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
PP&E Net
$3.1B
|
CAGR 3-Years
28%
|
CAGR 5-Years
19%
|
CAGR 10-Years
16%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
PP&E Net
$5.1B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
12%
|
|
Anika Therapeutics Inc
Glance View
Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. The company is headquartered in Bedford, Massachusetts and currently employs 297 full-time employees. The firm is focused on developing, manufacturing, and commercializing products based on its hyaluronic acid (HA) technology platform. The Company’s product include OA Pain Management product consists of Monovisc and Orthovisc, which is single and multi-injection, HA-based viscosupplement product, Cingal, and Hyvisc; Joint Preservation and Restoration product consists of bone preserving joint technologies, soft tissue repair and regenerative solutions, and Non-Orthopedic product consists of Hyalobarrier, an anti-adhesion barrier indicated for use after abdomino-pelvic surgeries. Hyalomatrix is used for the treatment of wounds, such as burns, ulcers, ears, nose and throat disorders, and ophthalmic products.
See Also
What is Anika Therapeutics Inc's PP&E Net?
PP&E Net
66.3m
USD
Based on the financial report for Dec 31, 2025, Anika Therapeutics Inc's PP&E Net amounts to 66.3m USD.
What is Anika Therapeutics Inc's PP&E Net growth rate?
PP&E Net CAGR 10Y
5%
Over the last year, the PP&E Net growth was 2%. The average annual PP&E Net growth rates for Anika Therapeutics Inc have been -6% over the past three years , -2% over the past five years , and 5% over the past ten years .
